A carregar...

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies

PURPOSE: Targeted therapies have resulted in major advances in the treatment of HER2-positive breast cancers. Despite this, up to 70% of patients will develop resistance to treatment within 2 years and new strategies for targeting resistant disease are needed. METHODS: To identify potential resistan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Tracey, Natasha, Creedon, Helen, Kemp, Alain J., Culley, Jayne, Muir, Morwenna, Klinowska, Teresa, Brunton, Valerie G.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6997276/
https://ncbi.nlm.nih.gov/pubmed/31705351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-019-05489-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!